Fabio L. M. Ricciardolo (Orbassano (Turin), Italy), Fusun Yildiz (Kocaeli, Turkey), Isabelle Vachier (Montpellier, France), Chair to be confirmed
QVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: A pooled analysis of LANTERN and ILLUMINATE
Wisia Wedzicha (London, United Kingdom), Jadwiga A. Wedzicha, David Price, Karen Mezzi, Robert Fogel, Donald Banerji
|  |
Baseline symptom scores and future risk of severe exacerbation: The SPARK study
Wisia Wedzicha (London, United Kingdom), Jadwiga A. Wedzicha, Karen Mezzi, Robert Fogel, Donald Banerji
|  |
The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast
Iryna Savelikhina (Ivano-Frankivsk, Ukraine), Mykola Ostrovskyy, Oleksandr Varunkiv, Iryna Savelikhina, Mariana Kulynych-Miskiv
| |
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
Christian Gessner (Leipzig, Germany), Christian Gessner, Wolfgang Schürmann, Karin Förster, Christian Sieder, Simone Hiltl, Roland Buhl, Stephanie Korn
| |
Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groups
Anthony D. D'Urzo (Toronto, Canada), Anthony D’Urzo, Giovanni Bader, Pablo Altman, Pankaj Goyal
| |
Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups
Anthony D. D'Urzo (Toronto, Canada), Anthony D’Urzo, Giovanni Bader, Pablo Altman, Pankaj Goyal
| |
The effects of inhaler B-2 adrenergic agonists on esophaeal high resolution manometry pressure metrics in asthma patients with inadequate symptom control (Ege University reflux group)
Özlem Göksel (Izmir, Turkey), Ozlem Goksel, Rukiye Vardar, Haydar S. Karakus, Yasemin Alev, Esra Yildirim, Munevver Erdinc, Serhat Bor
| |
Changes in symptoms, respiratory function, airway inflammation, and airway hyperresponsiveness over 10 year of inhaled corticosteroid therapy in adult asthma patients
Terufumi Shimoda (Fukuoka, Japan), Terufumi Shimoda, Yasushi Obase, Michiyoshi Imaoka, Reiko Kishikawa, Tomoaki Iwanaga
| |
Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD
James F. Donohue (Chapel Hill, United States of America), James F. Donohue, Paul Jones, Christian Bartels, Jessica Marvel, Peter D’Andrea, Donald Banerji, Francesco Patalano, Robert Fogel
| |
Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study
Jose M. Marin Trigo (Zaragoza, Spain), Jose Mª Marin, Andreas Clemens, Ricard Casamor, Walter Castellani, Lennart Schaper, Dinesh Saralaya, Anthony Gunstone, Konstantinos Kostikas, Maryam Aalamian-Mattheis, Kai Beeh
| |
Cigarette smoke extract (CSE) promotes acetylcholine (ACh) mediated inflammation and oxidative stress by PEBP1/Raf-mediated MEK and ERK pathway in human bronchial epithelial cells
Giusy D Albano (Palermo, Italy), Giusy D. Albano, Anna Bonanno, Loredana Riccobono, Rosalia Gagliardo, Michael Pieper, Mark Gjomarkaj, Mirella Profita
| |
Does omalizumab attenuate blood eosinophilia at 52 weeks; a single centre observation
Moshfiq Abeer (Hull, United Kingdom), Moshfiq Abeer, Thompson Joanne, Cummings Helena, Watkins Karen, Jaymin Morjaria
| |
Cromoglycate: Breathing life into an old asthma drug
Sarah Maher (London, United Kingdom), Sarah Maher, Mark Birrell, Katie Baker, Kristof Raemdonck, Sara Bonvini, John Adcock, Michael Wortley, Eric Dubuis, Fisnik Shala, Victoria Jones, Peter Barnes, Rajamannar Thennati, Biswajit Samanta, Dipali Desai, Anil Kumbhani, Maria Belvisi
| |
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Tanya Kralimarkova (Sofia, Bulgaria), Tanya Kralimarkova, Maria Staevska, Tsvetelina Lazarova, Diana Hristova, Vasil Dimitrov, Todor Popov
| |
Lung function change and exacerbations in patients with COPD in the WISDOM study
Henrik Watz (Grosshansdorf, Germany), Henrik Watz, Helgo Magnussen, Anne Kirsten, Kay Tetzlaff, Helen Finnigan, Bernd Disse, Eric Bateman
| |
Indirect comparison of bronchial thermoplasty (BT) versus omalizumab (OM) for severe uncontrolled asthma
Robert Niven (Manchester, United Kingdom), Robert Niven, Michael Simmonds, Michael Cangelosi, Narinder Shargill, Dominic Tilden, Suzanne Cottrell
| |
Effect of inhaled beclomethasone or placebo on brain stem activity in a patient chronically treated with steroids - Preliminary report
Zygmunt Podolec (Kraków, Poland), Zygmunt Podolec, Marcin Hartel, Daria Panek, Magdalena Podolec-Rubis, Tomasz Banasik
| |
Difference in resistance to humidity between commonly used dry powder inhalers
Thomas LÖÖf (Mölndal, Sweden), Thomas Lööf, Gunilla Telg, Georgios Stratelis, Jan-Olof Svensson
| |
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
Andrea Rossi (Verona, Italy), Andrea Rossi, Thys Van der Molen, Ricardo Del Olmo, Alberto Papi, Luis Wehbe, Matthew Quinn, Chengxing Lu, David Young, Ray Cameron, Pablo Altman
| |